# OnCo record nct02568267 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct02568267/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct02568267", "NCT02568267" ;
  schema:name "Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangeme"@en ;
  schema:alternateName "STARTRK-2"@en ;
  schema:description "A phase 2 trial of Entrectinib in colorectal cancer and melanoma, run by Hoffmann-La Roche, active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct02568267/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT02568267>, <https://doi.org/10.1016/S1470-2045(19)30691-6>, <https://www.nice.org.uk/guidance/ta643> ;
  onco:status "active" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "2" ;
  schema:startDate "2015-11-19" ;
  onco:cancers <https://onco.cc/cancers/colorectal/>, <https://onco.cc/cancers/melanoma/>, <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/sclc/>, <https://onco.cc/cancers/ovarian/>, <https://onco.cc/cancers/ros1-positive-nsclc/>, <https://onco.cc/cancers/ntrk-fusion-nsclc/>, <https://onco.cc/cancers/alk-positive-nsclc/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:drugs <https://onco.cc/drugs/entrectinib/> ;
  onco:companies <https://onco.cc/companies/roche-genentech/> ;
  onco:trials <https://onco.cc/trials/profile-1001-ros1/>, <https://onco.cc/trials/nct03093116/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-drilon-entrectinib-ros1-lancet-oncol-2020/> .